Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

Good morning. Today is Thursday, February 19th. I'm Julie Morgan. Carvana sold more cars than Wall Street expected in the fourth quarter.

But concerns over the company's profitability have pushed the

stock into the red this morning. Carvana is down 16% in pre-market action. The use card marketplace

experienced a 58% surge in revenue. On a per unit basis, retail vehicle sales were up 43% while wholesale increased 66%. However, when you break down the numbers further, it shows a $244 decline in gross profit per vehicle and an 18.2% decline in wholesale marketplace gross profit. The company's profitability gave a

mixed picture as adjusted iBada increased to $511 million but missed the $539 million estimate.

While on a per share basis, adjusted profits surged to $4.22 per share from 56 cents per share, although this was attributed to

one-time charges and so is not comparable to $1.12 estimates. The company did not issue sales

guidance for the full year, but said it continues to expect to sell 3 million cars between 2030 and 2035.

DoorDash is up 13% in pre-market trading.

shares surged as strong order growth and upbeat guidance outweighed a Q4 top and bottom line miss.

Orders climb 32% to 903 million million and gross order value jumped 39% to

$29.7 billion, both above expectations. The Q1 Outlook for GOV and EBITA came in strong,

$31 to $31.8 billion in $675 to $775 million, respectively.

Investors look past softer margins and heavy investment spending, choosing to focus on demand,

momentum and growth visibility.

Now we have an update to a story we brought you last week here on Wall Street Breakfast.

Moderna closed 6% higher on Wednesday after the USFDA accepted the company's marketing application

for its messenger RNA-based shot MRNA 1010, reversing an earlier stance to refuse its review.

In a press release, the biotech said that the agency

has also assigned August 5th of this year as the target action date in connection with its

biologics license application for MRNA 1010. Shares of Moderna came under pressure last week

...